个体化血管医学：个体化药物治疗。
Personalized vascular medicine: individualizing drug therapy.
机构信息
Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, USA.
出版信息
Vasc Med. 2011 Oct;16(5):391-404. doi: 10.1177/1358863X11422251.
Abstract
Personalized medicine refers to the application of an individual's biological fingerprint - the comprehensive dataset of unique biological information - to optimize medical care. While the principle itself is straightforward, its implementation remains challenging. Advances in pharmacogenomics as well as functional assays of vascular biology now permit improved characterization of an individual's response to medical therapy for vascular disease. This review describes novel strategies designed to permit tailoring of four major pharmacotherapeutic drug classes within vascular medicine: antiplatelet therapy, antihypertensive therapy, lipid-lowering therapy, and antithrombotic therapy. Translation to routine clinical practice awaits the results of ongoing randomized clinical trials comparing personalized approaches with standard of care management.
摘要
个性化医疗是指应用个体的生物指纹 - 即独特的生物信息综合数据集 - 来优化医疗护理。虽然这一原则本身很简单，但实施起来仍然具有挑战性。药物基因组学的进步以及血管生物学的功能检测现在使得对个体对血管疾病的医疗治疗的反应进行更好地描述成为可能。这篇综述描述了旨在允许对血管医学中的四大类主要药物治疗类别进行定制的新策略：抗血小板治疗、降压治疗、降脂治疗和抗血栓治疗。将其转化为常规临床实践需要等待正在进行的比较个性化方法与标准护理管理的随机临床试验的结果。
相似文献
1
Personalized vascular medicine: individualizing drug therapy.个体化血管医学：个体化药物治疗。
Vasc Med. 2011 Oct;16(5):391-404. doi: 10.1177/1358863X11422251.
2
Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.抗高血压和降脂治疗的心血管药物遗传学
Curr Mol Med. 2014;14(7):849-79. doi: 10.2174/1566524014666140811115517.
3
The next 10 years in personalized medicine in cardiology.心脏病学个性化医疗的未来十年。
Expert Rev Cardiovasc Ther. 2013 Aug;11(8):933-5. doi: 10.1586/14779072.2013.814823.
4
Novel treatments for cardiovascular disease prevention.用于心血管疾病预防的新疗法。
Cardiovasc Ther. 2012 Oct;30(5):257-63. doi: 10.1111/j.1755-5922.2011.00280.x. Epub 2011 May 31.
5
The Role of Pharmacogenetics in Antithrombotic Therapy Management: New Achievements and Barriers Yet to Overcome.药物遗传学在抗血栓治疗管理中的作用：新成就与尚待克服的障碍
Curr Med Chem. 2021;28(32):6675-6703. doi: 10.2174/0929867328666201231124715.
6
Personalized medicine and antiplatelet therapy: ready for prime time?个性化医疗与抗血小板治疗：准备好进入黄金时代了吗？
Eur Heart J. 2009 Aug;30(16):1943-63. doi: 10.1093/eurheartj/ehp295. Epub 2009 Jul 28.
7
The pharmacogenetics of antiplatelet agents: towards personalized therapy?抗血小板药物的药物遗传学：迈向个体化治疗？
Nat Rev Cardiol. 2011 Aug 9;8(10):560-71. doi: 10.1038/nrcardio.2011.111.
8
Comprehensive medical management of peripheral arterial disease.外周动脉疾病的综合医学管理。
Prog Cardiovasc Dis. 2011 Jul-Aug;54(1):2-13. doi: 10.1016/j.pcad.2011.02.004.
9
Medical and lifestyle management of peripheral arterial disease.外周动脉疾病的医学与生活方式管理
J Vasc Surg. 2018 Nov;68(5):1595-1606. doi: 10.1016/j.jvs.2018.07.027.
10
Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis.基于证据的心血管疾病二级预防治疗效果：系统评价和荟萃分析。
PLoS One. 2019 Jan 18;14(1):e0210988. doi: 10.1371/journal.pone.0210988. eCollection 2019.
引用本文的文献
1
The Association between Gly460Trp-Polymorphism of Alpha-Adducin 1 Gene () and Arterial Hypertension Development in Ukrainian Population.乌克兰人群中α-内收蛋白1基因（）Gly460Trp多态性与动脉高血压发生之间的关联。
Int J Hypertens. 2021 May 4;2021:5596974. doi: 10.1155/2021/5596974. eCollection 2021.
2
Quantile-dependent expressivity of postprandial lipemia.餐后血脂依赖性表达。
PLoS One. 2020 Feb 26;15(2):e0229495. doi: 10.1371/journal.pone.0229495. eCollection 2020.
3
Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity.经皮冠状动脉介入治疗后缺血事件的预测：血栓弹力图特征与凝血因子XIIIa活性
TH Open. 2018 Apr;2(2):e173-e181. doi: 10.1055/s-0038-1645876.
4
Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.进行性肾功能减退是1型糖尿病中糖尿病肾病的主要特征。
Clin Exp Nephrol. 2014 Aug;18(4):571-83. doi: 10.1007/s10157-013-0900-y. Epub 2013 Nov 12.
5
Personalized medicine in cardiovascular diseases.心血管疾病的个性化医学。
Korean Circ J. 2012 Sep;42(9):583-91. doi: 10.4070/kcj.2012.42.9.583. Epub 2012 Sep 27.
6
High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.1 型糖尿病患者发生终末期肾病的风险高：需要新策略来延缓肾功能进行性下降。
Semin Nephrol. 2012 Sep;32(5):407-14. doi: 10.1016/j.semnephrol.2012.07.002.
本文引用的文献
1
Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin.使用基因检测的个性化医疗对医疗保健的影响：对华法林的探索性分析。
Per Med. 2008 May;5(3):279-284. doi: 10.2217/17410541.5.3.279.
2
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.华法林预防深静脉血栓形成（DVT）的遗传学信息学试验（GIFT）：基本原理和研究设计。
Pharmacogenomics J. 2012 Oct;12(5):417-24. doi: 10.1038/tpj.2011.18. Epub 2011 May 24.
3
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.根据细胞色素 P450 2C19 基因型，急性心肌梗死患者中联合西洛他唑与高维持剂量氯吡格雷的血小板抑制作用。
JACC Cardiovasc Interv. 2011 Apr;4(4):381-91. doi: 10.1016/j.jcin.2010.12.010.
4
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.基于经皮冠状动脉介入治疗后血小板功能检测的标准剂量与高剂量氯吡格雷：GRAVITAS 随机试验。
JAMA. 2011 Mar 16;305(11):1097-105. doi: 10.1001/jama.2011.290.
5
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.SLCO1B1 基因 rs4149056 变异对辛伐他汀和阿托伐他汀相关肌病的影响差异。
Pharmacogenomics J. 2012 Jun;12(3):233-7. doi: 10.1038/tpj.2010.92. Epub 2011 Jan 18.
6
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.多中心随机试验评估西洛他唑在冠心病药物洗脱支架置入后缺血性血管并发症中的疗效：CILON-T（西洛他唑三联抗血小板治疗对药物洗脱支架置入后缺血性并发症的影响）试验结果。
J Am Coll Cardiol. 2011 Jan 18;57(3):280-9. doi: 10.1016/j.jacc.2010.08.631.
7
8
The relationship of vitamin D deficiency to statin myopathy.维生素 D 缺乏与他汀类药物肌病的关系。
Atherosclerosis. 2011 Mar;215(1):23-9. doi: 10.1016/j.atherosclerosis.2010.11.039. Epub 2010 Dec 5.
9
Paraoxonase-1 is a major determinant of clopidogrel efficacy.对氧磷酶 1 是氯吡格雷疗效的主要决定因素。
Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19.
10
Aspirin resistance: Fact or fiction? A point of view.阿司匹林抵抗：事实还是虚构？一种观点。
World J Cardiol. 2010 Sep 26;2(9):280-8. doi: 10.4330/wjc.v2.i9.280.
Zotero 插件